Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foscarnet vs Ganciclovir in CMV Retinitis
NCT00000136Phase 3Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Mar 1990
- Primary completion
- Oct 1991
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, open-label trial in cytomegalovirus retinitis comparing Foscarnet with Ganciclovir (2 arms). Primary endpoint: Mortality at 1 year. Started Mar 1990; status: completed.
02
Drugs
foscarnet sodiumganciclovir
03
Conditions
cytomegalovirus retinitis
Beyond the preview
Go deeper on NCT00000136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000136.